free webinar

The Next Billion-Dollar Acquisition in Pharma -

A Forward-Looking Patent Analysis on Bristol-Myers Squibb Acquiring Celgene

Monday, February 11
2:00 PM EST

Global timing:

11:00 AM PST

7:00 PM GMT

8:00 PM CET

Learn how the $74 billion deal between Bristol-Myers Squibb and Celgene will affect the innovation landscape in the pharmaceutical industry.

Register by filling out the form!


How can I effectively spot Acquisition Targets and their Technological Fit?

How can I model Divestiture Scenarios and their Effect on the Technology Landscape?

Register now and find answers!

this webinar starts in

2019/02/11 2:00 PM EST

What You’ll Learn


Scan the Worldwide Technology Landscape for Suitable Acquisition Targets 

Create Deep Analysis for Board Room Presentation

How to Identify Acquisition Targets and Alternatives

How to Identify if the Target's Patent Portfolio will be an Asset or a Liability

How to Leveraging Clean Data and Intelligent Analytics

Find Key Patents and Critical IP Issues


Don't Miss Out. Reserve Your Space.


About The Hosts

Gene Quinn
President and Founder,
Gene Quinn is the president and founder of, a patent attorney, law professor, and leading commentator on patent law and innovation policy. Gene’s writings typically focus on pending legislation, rule making at the United States Patent and Trademark Office, and general commentary about the state of the industry. Gene practices patent law with Widerman Malek, and the majority of his patent practice is focused on software patents and Internet innovations. Since 2000 he has also been a principal lecturer in the PLI Patent Bar Review Course.
Marco Richter
Head of Consulting & Customer Success at PatentSight

Marco is the Head of Consulting & Customer Success at PatentSight – A LexisNexis Company. Marco has a strong consulting background in patent analytics, providing insights in dozens of projects to Fortune 500 and DAX companies. As a strategic consultant he has guided the transition of many patent departments to turn from an administrative patent function into an internal consulting unit. With PatentSight’s deep understanding of customer needs and challenges, he empowers his team to transfer this knowledge into our global customer community.  “PatentSight Customer Success goes a great distance to understand our business and our pain points. Their support is outstanding and they really help us generating value” – quote from a recent customer survey that summarizes the work of PatentSight’s Consulting & Customer Success team.

Kevin Noonan
Partner with McDonnell Boehnen Hulbert & Berghoff LLP and serves as Chair of the firm’s Biotechnology & Pharmaceuticals Practice Group
Kevin E. Noonan is a partner with McDonnell Boehnen Hulbert & Berghoff LLP and serves as Chair of the firm’s Biotechnology & Pharmaceuticals Practice Group. An experienced biotechnology patent lawyer, Dr. Noonan brings more than 20 years of extensive work as a molecular biologist studying high-technology problems in serving the unique needs of his clients. His practice involves all aspects of patent prosecution, interferences, and litigation. He represents pharmaceutical companies both large and small on a myriad of issues, as well as several universities in both patenting and licensing to outside investors. He has also filed amicus briefs in landmark patent and other cases to district courts, the Federal Circuit and the U.S. Supreme Court involving patenting issues relevant to biotechnology.

Limited Seats.
Reserve Your Space!

Register by filling out the form!